铁与性结肠炎相关的基因之间的显著相关性:对诊断和治疗的影响
Kai Zhang1, Kailing Wang2, Chengzhao Weng3
1Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China. zhang.kai@zsxmhospital.com.
European journal of medical research
|August 29, 2025
概括
这项研究确定了性结肠炎 (UC),一种类型的炎症性肠病 (IBD) 中与铁相关的关键基因. 这些基因具有诊断潜力,与免疫细胞透相关,为生物治疗提供了洞察力.
科学领域:
- 分子生物学
- 免疫学
- 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种主要的炎症性肠病 (IBD).
- 铁亡是一种受调节的细胞死亡途径,与各种疾病有关.
- 了解ferroptosis在UC中的作用对于开发向疗法至关重要.
研究的目的:
- 在性结肠炎 (UC) 中识别关键的铁相关基因.
- 评估这些基因在UC中的诊断和治疗潜力.
- 探索铁,免疫细胞透和UC之间的关系.
主要方法:
- 利用基因表达总数据库中的基因表达数据的生物信息分析.
- 在Dextran硫酸盐 (DSS) 诱导的小鼠结肠炎模型中验证了关键基因表达.
- 分析了UC患者的免疫细胞透及其与已确定的铁死相关基因的相关性.
主要成果:
- 在UC中鉴定出91个与铁相关的基因.
- 在小鼠大肠炎模型中,四个基因 (TIMP1,LPIN1,SOCS1,CD44) 显示出诊断价值,并被上调.
- 这些基因区分了治疗反应和活跃的UC患者,并与免疫细胞类型 (中性细胞,巨细胞,B细胞,NK细胞) 相相关.
结论:
- 免疫细胞透在UC显著与ferroptosis相关.
- 关键的铁与相关的基因具有UC诊断和预测治疗反应的潜力.
- 这些发现有助于了解UC背后的分子机制,并开发新的生物疗法.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
200
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
200
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
Peptic Ulcer Disease II: Pathophysiology
827
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
827
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
238
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
238


